Weiss Asset Management amends Theravance Biopharma stake
Ticker: TBPH · Form: SC 13D/A · Filed: Mar 5, 2024 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | SC 13D/A |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, schedule-13d
TL;DR
Weiss Asset Management just updated their Theravance Biopharma stake. Watch this space.
AI Summary
Weiss Asset Management LP, along with group members Andrew M. Weiss Ph.D., BIP GP LLC, and WAM GP LLC, filed an amendment (Amendment No. 2) to their Schedule 13D on March 5, 2024, regarding their holdings in Theravance Biopharma, Inc. The filing indicates a change in the group's beneficial ownership of the company's ordinary shares.
Why It Matters
This filing signals a potential shift in the ownership structure or strategy of Theravance Biopharma, Inc., which could influence its stock performance and future corporate actions.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to increased stock volatility.
Key Players & Entities
- Weiss Asset Management LP (company) — Filing entity
- Theravance Biopharma, Inc. (company) — Subject company
- Andrew M. Weiss Ph.D. (person) — Group member
- BIP GP LLC (company) — Group member
- WAM GP LLC (company) — Group member
FAQ
What is the specific nature of the change in beneficial ownership reported in this amendment?
The filing is an amendment (Amendment No. 2) to a Schedule 13D, indicating a change in the beneficial ownership of Theravance Biopharma, Inc. ordinary shares by the reporting group, but the exact nature of the change (increase, decrease, or other) is not detailed in the provided header information.
Who are the members of the reporting group filing this Schedule 13D/A?
The reporting group includes Weiss Asset Management LP, Andrew M. Weiss Ph.D., BIP GP LLC, and WAM GP LLC.
What is the CUSIP number for Theravance Biopharma, Inc. ordinary shares?
The CUSIP number for Theravance Biopharma, Inc. ordinary shares is G8807B106.
When was this Schedule 13D/A filing submitted to the SEC?
This Schedule 13D/A filing was submitted to the SEC on March 5, 2024.
What is the primary business of Theravance Biopharma, Inc. according to the filing?
Theravance Biopharma, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,132 words · 5 min read · ~4 pages · Grade level 9.8 · Accepted 2024-03-05 09:01:27
Filing Documents
- d781829dsc13da.htm (SC 13D/A) — 35KB
- 0001193125-24-058797.txt ( ) — 37KB
of the Schedule 13D is hereby amended and restated in its entirety as follows
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The percentages set forth in Row 13 and in this Item 5 have been calculated based on 48,164,708 shares of the Issuers Shares issued and outstanding as of February 23, 2024, as reported in the Issuers Form 10-K, filed with the SEC on March 1, 2024. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D/A shall not be deemed an admission of beneficial ownership of any Shares for any purpose. (a) and (b) 4,628,074 Shares, representing approximately 9.6% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. 2,828,986 Shares, representing approximately 5.9% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. See Rows 7-13 of the cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons. (c) The Reporting Persons did not effect any transactions in the Issuers Shares during the past 60 days. (d) Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares. (e) Not applicable. CUSIP No. G8807B106 13D/A Page 4 of 4 Pages
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete, and correct. March 5, 2024 WEISS ASSET MANAGEMENT LP BY: /S/ MARY FERRUOLO MARY FERRUOLO, AUTHORIZED SIGNATORY BIP GP LLC BY: /S/ MARY FERRUOLO MARY FERRUOLO, AUTHORIZED SIGNATORY WAM GP LLC BY: /S/ MARY FERRUOLO MARY FERRUOLO, AUTHORIZED SIGNATORY BY: /S/ MARY FERRUOLO MARY FERRUOLO, ATTORNEY-IN-FACT FOR ANDREW WEISS*** *** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on February 3, 2023 in respect of its holding in DEEP MEDICINE ACQUISITION CORP.